News
25 May 2020
KOLINPHARMA® obtains a patent in the United States of America for Dolatrox® - 10/03/2020
Dolatrox® is a composition for the treatment of arthropathies and osteoarthritis, as stated in the patent certificate. This composition was thus recognized as innovative and unique. Dolatrox is the 4th patent that Kolinpharma obtains in the USA.
"Obtaining the fourth patent, in a country like the United States, a worldwide reference in scientific research, is a huge source of pride for us" - comments the president, Rita Paola Petrelli.
Mentioned Companies
Kolinpharma
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
.png)
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
News Merck tests new formulation of Keytruda before the patent runs out
Merck tests new formulation of effective immunotherapy Keytruda to gain approval in time to extend the patent on the drug before it runs out in 2028. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain. -
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
.png)
News New vaccine technology utilising weakened DNA viruses
A new method of vaccine technology that employs weakened viruses has been developed to target DNA viruses that reproduce by making copies of their own DNA molecules, utilising a virus with altered DNA to fight against them. -
News Bavarian Nordic pledges 2 million doses of monkeypox vaccine to the EU
Bavarian Nordic has been working on a monkeypox vaccine that has come under high demand from several governments, leading to the company coming to a supply agreement with The European Union.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance